Drug
Bepirovirsen clinical trials
Also written GSK3228836.
- studies test it
- 13
- open now
- 1
- in phase 3
- 2
- first study started
- 2017
Keep track of what changes. Save the bepirovirsen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
GlaxoSmithKline (12) · National University Health System, Singapore (1)
Often tested with
Tested in the same studies.
GSK-3965193 (1)
Studies
Open first, then newest update. How each study uses bepirovirsen is read from its arms, and is right about nine times in ten.
Testing it · 13
- Bepirovirsen Liver Biopsy StudyNot yet recruitingPhase 2National University Health System, SingaporeNCT07696520Written as Bepirovirsen
- Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B InfectionTerminatedPhase 1/2GlaxoSmithKlineNCT05330455Written as Bepirovirsen
- Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT06422767Written as Bepirovirsen
- Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)Active, not recruitingPhase 2GlaxoSmithKlineNCT06497504Written as Bepirovirsen
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)CompletedPhase 3GlaxoSmithKlineNCT05630820Written as Bepirovirsen
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)CompletedPhase 3GlaxoSmithKlineNCT05630807Written as Bepirovirsen
- Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)Active, not recruitingPhase 2GlaxoSmithKlineNCT04954859Written as Bepirovirsen
- A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney DiseaseActive, not recruitingPhase 1GlaxoSmithKlineNCT07168356Written as Bepirovirsen
- A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult ParticipantsCompletedPhase 1GlaxoSmithKlineNCT06058390Written as Bepirovirsen
- A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis BCompletedPhase 2GlaxoSmithKlineNCT04544956Written as GSK3228836
- Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)CompletedPhase 2GlaxoSmithKlineNCT04676724Written as GSK3228836
- Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic ImpairmentCompletedPhase 1GlaxoSmithKlineNCT04971928Written as GSK3228836
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV InfectionCompletedPhase 2GlaxoSmithKlineNCT02981602Written as IONIS-HBVRx
Given in every arm · 3 — bepirovirsen is usual care beside what is tested
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)Active, not recruitingPhase 2GlaxoSmithKlineNCT06537414Written as Bepirovirsen
- A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) TherapyCompletedPhase 2GlaxoSmithKlineNCT05276297Written as GSK3228836
- A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)CompletedPhase 2GlaxoSmithKlineNCT04449029Written as GSK3228836
Codes
What other systems call bepirovirsen · ClinicalTrials.gg INT018668
- UNII (FDA) Z87O6SM01NBEPIROVIRSENOne source FDA
- NCI Thesaurus C175748BepirovirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z87O6SM01N | BEPIROVIRSEN | One source FDA |
| NCI Thesaurus | C175748 | Bepirovirsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.